|
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
This indicates that the gene(s) on the 17p13.3 region of the human chromosome may be influencing the p53 immunopositivity status of glial tumors and possibly other tumors in general.
|
10840825 |
2000 |
|
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Microsatellite instability, PTEN and p53 germline mutations in glioma families.
|
11669337 |
2001 |
|
Glioma
|
0.900 |
Biomarker
|
disease |
CTD_human |
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility.
|
21946351 |
2011 |
|
Glioma
|
0.900 |
AlteredExpression
|
disease |
LHGDN |
These results show for the first time that Notch-1 upregulates EGFR expression and also demonstrate Notch-1 regulation of p53 in gliomas.
|
18359760 |
2008 |
|
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
In conclusion, this bioinformatics analysis indicated that DEGs and core genes, such as TP53, might influence the development of glioma, especially in tumor proliferation, which were expected to be promising biomarkers for diagnosis and treatment of glioma.
|
30405856 |
2018 |
|
Glioma
|
0.900 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies multiple susceptibility loci for glioma.
|
26424050 |
2015 |
|
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We previously investigated IDH1/2 and TP53 mutations via Sanger sequencing for adult supratentorial gliomas and reported that PCR-based sequence analysis classified gliomas into three genetic subgroups that have a strong association with patient prognosis: IDH mutant gliomas without TP53 mutations, IDH and TP53 mutant gliomas, and IDH wild-type gliomas.
|
27837434 |
2017 |
|
Glioma
|
0.900 |
AlteredExpression
|
disease |
LHGDN |
Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin.
|
16327987 |
2006 |
|
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We analysed p53 and p14arf in relation with five other genetic loci encoding the most frequently mutated genes in human gliomas: cdkn2a, mdm2, egfr, pten and the chromosomal regions 10q23.3 and 10q25-26.
|
10949938 |
2000 |
|
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
To override the resistance mechanism of glioma cells with p53 mutation to radiation, we transduced U-373MG malignant astrocytoma (glioma) cells harboring mutant p53 with Fas ligand via an adenovirus (Adv) vector in combination with X-ray irradiation, and evaluated the degree of apoptosis.
|
11050476 |
2000 |
|
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Glioma development is accelerated upon loss of the tumor suppressor p53.
|
20360385 |
2010 |
|
Glioma
|
0.900 |
PosttranslationalModification
|
disease |
LHGDN |
In a panel of glioma cell lines, the status of the P53 gene was analyzed by temperature gradient gel electrophoresis (TGGE) of exons 5-8 and direct sequencing of all p53 exons.
|
15816541 |
2005 |
|
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Absence of a functional p53 increases TMZ sensitivity in traditional glioma cell lines, an effect that is independent of MGMT status, and not seen in BTICs.
|
20593219 |
2011 |
|
Glioma
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
We have previously shown that massive apoptosis occurs when wild-type p53 or E2F-1 expression is induced in glioma.
|
9864390 |
1999 |
|
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Because p53 is frequently mutated in brain tumors and the ING1 locus maps to a site of which the loss is associated with gliomas, we analyzed the mutation and expression profiles of ING1B in human brain tumors.
|
14676120 |
2003 |
|
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We found mutations in the p53 gene in eight of 22 adult glioma tissue specimens and germline mutations in two of these eight patients.
|
7664239 |
1995 |
|
Glioma
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that in pediatric high-grade gliomas: (i) histological grading does not have strong prognostic significance, (ii) YKL-40 overexpression is less frequent than adult high-grade gliomas and does not correlate with a more aggressive behavior, (iii) TP53 mutations but not p53 expression may correlate with a more aggressive behavior, and (iv) IDH1 mutations are absent.
|
20174854 |
2010 |
|
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
As mutations of the p53 tumor suppressor gene represent an early event in the development of gliomas, we attempted to determine whether both components of gliosarcomas share identical alterations of the p53 gene.
|
7666053 |
1995 |
|
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
A genomic analysis of the six genes identified in the glioma pathway by cBioPortal indicated that TMZ might exert biological effects via interaction with the tumor protein P53(TP53) signaling axis.
|
29152101 |
2017 |
|
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we tested the hypothesis that polymorphisms and haplotypes in p53 and ATM could be associated with glioma and meningioma risk.
|
17151932 |
2007 |
|
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Our results, combined with previous studies, ascertain the potential role of the TP53 gene to glioma onset.
|
23573956 |
2013 |
|
Glioma
|
0.900 |
Biomarker
|
disease |
LHGDN |
Furthermore, P53R3 enhances recruitment of endogenous p53 to several target promoters in glioma cells bearing mutant (T98G) and wild-type (LNT-229) p53 and induces mRNA expression of numerous p53 target genes in a p53-dependent manner.
|
18202704 |
2008 |
|
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
The expression level of MDM4-B mRNA detected by real-time PCR was not only significantly associated with tumor stages, but also with p53 mutation and Ki-67 status which are important clinical molecular markers of glioma.
|
23994448 |
2013 |
|
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Timing and role of p53 gene mutation in the recurrence of glioma.
|
1953716 |
1991 |
|
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
One on chromosome 8 increases risk of IDH-mutated gliomas sixfold and another that affects TP53 function confers a 2.5-fold increased risk of glioma.
|
26948345 |
2016 |